Newsroom

Insurers begin to review coverage of costly cholesterol drugs

“With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market,” John Rother, leader of the Campaign for Sustainable Rx Pricing, said in a statement.

Read more

FDA Approves New Cholesterol-Lowering Treatments

“The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.”

Read more

Prescription Drug Pricing: Give the People What They Want

Our effort—the Campaign for Sustainable Rx Prices—has been sounding the alarm for more than a year that pharmaceutical companies must come to the table with meaningful solutions to the challenge of rising drug costs. Otherwise, companies risk the rising tide of consumer anger resulting in solutions that are not constructive for anyone.

Read more

New KFF Poll: Unsustainable drug pricing moves ahead of ACA as GOP voters’ top health care concern

PRESS STATEMENT For Immediate Release August 20, 2015 Contact: John Rother JRother@nchc.org New KFF Poll: Unsustainable drug pricing moves ahead of ACA as GOP voters’ top […]

Read more